BRÈVE

sur MedMira, Inc. (CVE:MIR)

MedMira's Syphilis Test Receives FDA Breakthrough Device Designation

MedMira Inc., a company known for developing rapid diagnostic technologies, has received the U.S. FDA Breakthrough Device Designation for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test. This acknowledgement comes from the FDA's Center for Devices and Radiological Health, highlighting the device's potential to improve syphilis diagnosis, a significant public health challenge globally.

The test utilizes MedMira's Rapid Vertical Flow Technology, allowing simultaneous detection of treponemal and non-treponemal antibodies from a single blood sample. This contrasts with traditional methods requiring multiple procedures and infrastructure. The test may be particularly beneficial in areas with limited access to laboratory services.

The FDA's designation aims to accelerate the test's development and regulatory processes. However, it is not equivalent to FDA clearance for commercial use. MedMira sees this as an essential step in enhancing healthcare accessibility and hopes for further collaboration with the FDA.

R. H.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de MedMira, Inc.